

Camilla Hage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4379102/publications.pdf>

Version: 2024-02-01

70
papers

2,221
citations

270111

25
h-index

286692

43
g-index

71
all docs

71
docs citations

71
times ranked

3235
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation science and potential for screening in heart failure. <i>European Heart Journal</i> , 2022, 43, 413-415.	1.0	7
2	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGONâ€”CHF trial. <i>ESC Heart Failure</i> , 2022, 9, 164-177.	1.4	5
3	Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 681-684.	2.9	16
4	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fractionâ€”insights from the <sc>ESCâ€”HFA EORP</sc> Heart Failure Longâ€”Term Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 335-350.	2.9	49
5	Biomarker changes as surrogate endpoints in earlyâ€”phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	1.4	4
6	Use of evidenceâ€”based therapy in heart failure with reduced ejection fraction across age strata. <i>European Journal of Heart Failure</i> , 2022, 24, 1047-1062.	2.9	37
7	Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study. <i>ESC Heart Failure</i> , 2022, 9, 2125-2138.	1.4	3
8	Factors associated with healthâ€”related quality of life in heart failure in 23,000 patients from 40 countries: Results of the <sc>Gâ€”CHF</sc> Research Program. <i>European Journal of Heart Failure</i> , 2022, , , .	2.9	4
9	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heartâ€”Failure Phenotypes in the Swedishâ€”HF Registry. <i>JACC: Heart Failure</i> , 2022, 10, 380-392.	1.9	5
10	Effect of dipeptidyl peptidaseâ€”4 inhibitors on complement activation. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3385.	1.7	4
11	Reorganization of heart failure management and improved outcome â€” the 4D HF Project. <i>Scandinavian Cardiovascular Journal</i> , 2021, 55, 1-8.	0.4	6
12	The Differential Impact of the Left Atrial Pressure Components on Pulmonary Arterial Complianceâ€”Resistance Relationship in Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 277-285.	0.7	5
13	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. <i>Scientific Reports</i> , 2021, 11, 4885.	1.6	31
14	Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. <i>Journal of Cardiac Failure</i> , 2021, 27, 756-765.	0.7	20
15	Predictors of longâ€”term outcome in heart failure with preserved ejection fraction: a followâ€”up from the <sc>KaRen</sc> study. <i>ESC Heart Failure</i> , 2021, 8, 4243-4254.	1.4	13
16	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry. <i>International Journal of Cardiology</i> , 2021, 343, 63-72.	0.8	23
17	Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. <i>Journal of Cardiac Failure</i> , 2020, 26, 673-684.	0.7	5
18	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 2029-2044.	1.6	117

#	ARTICLE	IF	CITATIONS
19	Metabolomic Profile in HFpEF vs HFrEF Patients. <i>Journal of Cardiac Failure</i> , 2020, 26, 1050-1059.	0.7	46
20	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 1016-1021.	0.7	29
21	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , 2020, 127, 1261-1273.	2.0	38
22	Heart failure with preserved ejection fraction: A clustering approach to a heterogenous syndrome. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 381-390.	0.7	23
23	Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients. <i>ESC Heart Failure</i> , 2020, 7, 1534-1546.	1.4	28
24	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. <i>American Heart Journal</i> , 2020, 227, 56-63.	1.2	24
25	Increased iron absorption in patients with chronic heart failure and iron deficiency. <i>Journal of Cardiac Failure</i> , 2020, 26, 440-443.	0.7	7
26	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020, 7, 2098-2112.	1.4	23
27	The transition from hypertension to hypertensive heart disease and heart failure: the PREFERS Hypertension study. <i>ESC Heart Failure</i> , 2020, 7, 737-746.	1.4	22
28	Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. <i>Heart</i> , 2020, 106, 342-349.	1.2	89
29	Circulating neuregulin1 ^{ΔE2} in heart failure with preserved and reduced left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 445-455.	1.4	11
30	Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study. <i>International Journal of Cardiology</i> , 2019, 274, 202-207.	0.8	10
31	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2019, 140, 1359-1361.	1.6	16
32	Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 830-839.	1.4	18
33	Transcriptomics of cardiac biopsies reveals differences in patients with or without diagnostic parameters for heart failure with preserved ejection fraction. <i>Scientific Reports</i> , 2019, 9, 3179.	1.6	35
34	ST2 in heart failure with preserved and reduced ejection fraction. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 21-27.	0.4	40
35	Left atrial strain improves estimation of filling pressures in heart failure: a simultaneous echocardiographic and invasive haemodynamic study. <i>Clinical Research in Cardiology</i> , 2019, 108, 703-715.	1.5	51
36	Haemodynamic effects of levosimendan in advanced but stable chronic heart failure. <i>ESC Heart Failure</i> , 2018, 5, 302-308.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. <i>JACC: Heart Failure</i> , 2018, 6, 246-256.	1.9	47
38	Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2018, 24, 365-374.	0.7	32
39	Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 121, 1558-1566.	0.7	19
40	Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome. <i>International Journal of Cardiology</i> , 2018, 267, 128-132.	0.8	28
41	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. <i>European Heart Journal</i> , 2018, 39, 3439-3450.	1.0	375
42	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	107
43	Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 629-635.	0.5	40
44	HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. <i>International Journal of Cardiology</i> , 2017, 228, 709-716.	0.8	38
45	The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study. <i>Heart and Vessels</i> , 2017, 32, 735-749.	0.5	6
46	Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. <i>International Journal of Cardiology</i> , 2017, 226, 65-70.	0.8	4
47	Copeptin in Heart Failure, Post-Left Ventricular Assist Device and Post-Heart Transplantation. <i>Heart Lung and Circulation</i> , 2017, 26, 143-149.	0.2	9
48	HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1. <i>Journal of Cardiac Failure</i> , 2017, 23, 293-303.	0.7	25
49	Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF). <i>International Journal of Cardiology</i> , 2016, 220, 750-758.	0.8	13
50	Rationale and design of the <sc>PREFERS</sc> (Preserved and Reduced Ejection Fraction) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 T Stockholm county of 2.1 million inhabitants. <i>European Journal of Heart Failure</i> , 2016, 18, 1287-1297.	2.9	17
51	Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	33
52	Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 307-311.	0.9	6
53	New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study. <i>European Journal of Heart Failure</i> , 2015, 17, 680-688.	2.9	77
54	Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity. <i>Growth Hormone and IGF Research</i> , 2015, 25, 298-303.	0.5	3

#	ARTICLE	IF	CITATIONS
55	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2015, 199, 415-423.	0.8	7
56	Prevalence and prognostic implications of anaemia and iron deficiency in Tanzanian patients with heart failure. <i>Heart</i> , 2015, 101, 592-599.	1.2	23
57	Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. <i>International Journal of Cardiology</i> , 2015, 189, 6-11.	0.8	17
58	Accuracy of a Simplified Glucose Measurement Device—The HemoCue Glucose 201RT. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 755-758.	2.4	16
59	Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. <i>Open Heart</i> , 2015, 2, e000260.	0.9	16
60	Abstract 12849: Changes in N-terminal Pro Brain Natriuretic Peptide Levels Predicts Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2015, 132, .	1.6	0
61	The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 290-293.	0.9	13
62	Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study. <i>Heart</i> , 2014, 100, 1235-1241.	1.2	93
63	Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 992-1001.	2.9	119
64	Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 112-121.	0.7	40
65	The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 143-149.	0.9	2
66	Glucose Monitoring by Means of an Intravenous Microdialysis Catheter Technique. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 291-295.	2.4	11
67	The impact of infarct type on the reliability of early oral glucose tolerance testing in patients with myocardial infarction. <i>International Journal of Cardiology</i> , 2010, 145, 259-260.	0.8	13
68	Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. <i>Diabetes and Vascular Disease Research</i> , 2009, 6, 71-79.	0.9	20
69	Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2009, 11, 198-204.	2.9	47
70	Long term effects of exercise training on physical activity level and quality of life in elderly coronary patients – A three- to six-year follow-up. <i>Physiotherapy Research International</i> , 2003, 8, 13-22.	0.7	29